Edwin De Jesus

Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.

M. Kozal, P. Cahn, J. Aberg, 2020, The lancet. HIV.